In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Micromet grosses $40mm privately

Executive Summary

Micromet (cancer, inflammation, and autoimmune disease antibodies) has grossed $40mm through the private sale of 9.4mm common shares at $4.25 each (an 8% discount). Investors also received five-year warrants to buy another 2.8mm shares at $4.63 apiece. Index Ventures Growth, Abingworth, DAFNA Capital Management, and Merlin Nexus participated and were joined by three Micromet directors and two funds affiliated with the members. The company will use the funds to continue clinical development of its antibodies, including BiTE blinatumomab (MT103/MEDI538) in Phase II for acute lympoblastic leukemia and in Phase I for non-Hodgkin's lymphoma. Piper Jaffray and RBC Capital Markets were the placement agents.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies